Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

.

Two previous studies with EVP-6124 in Alzheimer's disease patients demonstrated that it was well tolerated and produced significant effects on a variety of cognitive measures of brain function such as attention, memory and executive function (complex thinking tasks). EVP-6124 had procognitive effects in two separate clinical trials: one study conducted in Alzheimer's disease patients already treated with Acetyl Choline Esterase Inhibitors (AChEI) and one in Alzheimer's disease patients not on AChEI therapy (naive patients).

EVP-6124 is a selective agonist for the alpha-7 subtype of the nicotinic acetylcholine receptor and is being developed by EnVivo for potential cognitive enhancement in both schizophrenia and Alzheimer's patients. It has been shown to have excellent CNS penetration, oral bioavailability, pharmacokinetics and metabolic profile.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, cognitive disorders and schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which has completed Phase I studies, and seve
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... YORK , June 29, 2015   For the ... life sciences to assess their overall digital maturity called ... show that these companies are not maturing fast enough. ... healthcare industry in numerous ways overall and customers are ... in terms of digital customer engagement.  ...
(Date:6/26/2015)... VANCOUVER , June 26, 2015 /PRNewswire/ - iCo ... ICOTF), today announced that all nominees listed in ... as directors at its 2015 Annual Meeting of ... a vote by ballot, the following 5 nominees ... iCo Therapeutics to serve until the Company,s next ...
(Date:6/26/2015)... , ... June 26, 2015 , ... ... announced that its SimplePrep™ technologies have been integrated into a sample prep module ... Station (ISS) as a part of the NASA’s WetLab-2 Project. , On June ...
(Date:6/26/2015)... (PRWEB) , ... June 26, 2015 , ... ReliantHeart, ... that indicates that from the first implant of the HeartAssist5® LVAD (HA5) to the ... the HA5. , Thrombus that originates in an LVAD is referred to as ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3
... Industry Readiness and Questions Fiscal ... Delaying Biogenerics -, WASHINGTON, Sept. 6 Expensive ... patents,expire, and generic companies stand ready to add biogenerics ... legislation enabling the U.S.,Food and Drug Administration (FDA) to ...
... BSX ) today announced that the Company,s Board ... Mr. Elliott, 58, is Chairman of the Board of ... Chief Executive Officer of,Zimmer from 2001 to 2007 and ... and director experience in medical devices,orthopaedics and other industries. ...
... on September 13, 2007 at the 14th, International Symposium on Hepatitis ... ... in Glasgow, Scotland, VALLEY COTTAGE, New York, September 6 ... today,that a late breaker abstract, entitled "Potent Small Molecule HCV,Inhibitors Affecting ...
Cached Biology Technology:Biogenerics Will Save Billions, Says Hospira CEO 2Biogenerics Will Save Billions, Says Hospira CEO 3Biogenerics Will Save Billions, Says Hospira CEO 4Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 2Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 3XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference 2
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/15/2015)... June 15, 2015 A new report ... reveals the majority of US consumers using mobile banking applications ... such as fingerprint and voiceprint, instead of having to prove ... to Telstra,s " Mobile Identity   -   The Fusion ... with smartphones now the primary channel used by Gen X ...
(Date:6/9/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... will be providing demonstrations of its iMedNet ... Information Association (DIA) Annual Meeting in Washington ... include previews of many exciting new enhancements that will ... 2015 Feature 1 Release. MedNet ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... their marriage gain weight in the early years after ... various health problems related to being overweight. That ... satisfaction and weight gain, according to psychologist Andrea L. ... Methodist University in Dallas. "On average, spouses who ...
... body, called "angiogenesis," is usually discussed in connection with healing ... the female reproductive tract, where the growth and breaking of ... But abnormal growth of blood vessels can have painful consequences ... research associate Dr. Dana Chuderland of Tel Aviv University,s Sackler ...
... US$11.5 billion worth of fish from beyond their country,s own ... according to a new study led by fisheries scientists at ... in the journal Fish and Fisheries , estimates that ... it reports to the United Nation,s Food and Agriculture Organization, ...
Cached Biology News:Marriage can threaten health: Study finds satisfied newlyweds more likely to gain weight 2New relief for gynecological disorders 2New relief for gynecological disorders 3Chinese foreign fisheries catch 12 times more than reported: UBC research 2
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Biology Products: